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Advancing knowledge on cannabis policy using evidence from North America 
Alex Stevens 
Rosalie Liccardo Pacula 
[This is a pre-proof version of an editorial published in the April 2017 issue of the International 
Journal of Drug Policy, DOI: http://dx.doi.org/10.1016/j.drugpo.2017.02.004] 
For decades, drug policy campaigners around the world blamed the United States of America (USA) 
for the lack of change in international drug policy. The USA was seen as the most powerful supporter 
of the prohibitionist interpretation of the UN drug conventions, and as one its strictest domestic 
enforcers. The picture of the USA as chief architect of prohibition may always have been limiting 
(Collins, in press). It ignored, for example, the wave of decriminalisation that was implemented in 
many US states in the 1970s (Pacula et al., 2005; MacCoun and Reuter, 2001) as well as state efforts 
to make cannabis available for medicinal purposes in the 1990s and 2000s (Pacula and Smart, 2017; 
Hall and Pacula, 2003). It has been decisively challenged by more recent developments. The 
decisions by the electorates of Colorado and Washington to legalise the sale of cannabis for 
recreational use in November 2012 went further than the many states that had already permitted 
sale for medical purposes. These were followed by similar votes in two more states (Oregon and 
Alaska) and the District of Columbia in November 2014, and then four more states (California, 
Massachusetts, Maine and Nevada) in November 2016.  Today, more than 20% of U.S. population 
lives in a jurisdiction that has legalized cannabis for recreational purposes.    
Policy reform regarding recreational cannabis has not been limited to jurisdictions within the USA, 
however.   Uruguay successfully passed a law in 2013, allowing residents 18 years and older to either 
grow cannabis on their own, join a collective, or purchase from pharmacies (Kilmer and Pacula, 
2016) and in 2016 the  new Canadian government’s announced its intention to legalize cannabis as 
well  (Task Force on Cannabis Regulation and Legalization, 2016).  
It was in this context that the International Society for the Study of Drug Policy (ISSDP) co-hosted a 
meeting with the Marron Institute at NYU in New York City in April 2016. For the Marron Institute, 
this was the Cannabis Science and Policy Summit. It incorporated the ISSDP’s regional meeting on 
cannabis policy in the Americas. The papers published in this issue are mostly selected from those 
presented at the meeting, as well as relevant papers presented at the ISSDP’s 10th annual conference 
in Sydney. They focus on cannabis policy in North America, although we do also include a viewpoint 
on medical ganja in Jamaica (Jones, this issue) and legal cannabis in Uruguay (Kilmer and Cerda, this 
issue). 
One of the main aims of the ISSDP is to improve the use of evidence in drug policy. We know how 
difficult this can be (Stevens & Ritter, 2013). Evidence is rarely imported directly into policy in a 
linear fashion. The ‘enlightenment’ function of evidence may be blocked by the barriers that prevent 
policy makers from accessing evidence (Ritter, 2009), or by systematic distortion in the political uses 
of the research base (Stevens, 2011). Nevertheless, we believe that high quality research is the best 
way to inform public debate about the process, outcome and impacts of different drug policies.  
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This must start from a thorough understanding of what the effects of a drug – both positive and 
negative – can be.  Drs. Susan Weiss, Katia Howlett and Ruben Baler’s (this issue) article “Building 
Smart Cannabis Policy from the Science Up”  offers readers an overview of the current state of 
knowledge on the harms and medical benefits of the complex mix of compounds contained within 
the cannabis plant.  They focus on the mechanisms by which the known compounds can exert their 
effects on the body, through the endocannabinoid system, the neurological system, and executive 
functions of the brain.  This provides a strong biological basis for understanding the potential 
therapeutic benefits and harms associated with particular strains of the cannabis plant, which 
contain different mixes of these compounds.  It is within the context of this biological science related 
to the cannabis compounds that they then review the knowledge related to therapeutic benefits, 
acute effects, addiction, psychosis and impacts on the developing brain.      
In his article “Recognizing and Regulating Cannabis as a Temptation Good” Jonathan Caulkins (this 
issue) makes a provocative statement, explaining that perhaps the biggest impact of this cannabis 
legalization experiment that is being conducted today is not the savings from black markets or 
criminal justice, nor it is the health harms associated with use, but rather the hours of intoxication 
that will result. He argues that we can make use of experiences in the regulation of ‘temptation 
goods’ (e.g. alcohol). A common assumption is that most cannabis users do not use problematically, 
so that any increases in use that follow legalization will be largely non-problematic. Caulkins 
suggests, in direct contrast, that most cannabis is used by people who use it a lot, spending much of 
their time intoxicated. Caulkins’ informed speculation on the potential effects provide a necessary 
note of caution alongside more celebratory commentaries on cannabis legalization that have 
appeared elsewhere.  Wayne Hall (this issue) specifically addresses the adverse health effects of 
cannabis. He notes that comparisons with those of alcohol may be misleading, especially due to our 
lack of knowledge on effects of long-term cannabis use. Hall notes that the relatively regulatory 
framework that the USA and other countries have adopted for alcohol may not be the best model 
for dealing with cannabis. 
As Caulkins and Hall both make clear, we need to think about the potential effects of cannabis use 
and policy on specific groups within the broader population. The article by M.J. Milloy et al (this 
issue) looks at a particularly interesting group for drug policy; people who use drugs and are HIV 
positive. If cannabis use hinders anti-retroviral treatment for these people, then it would have a 
knock-on effect in increasing subsequent infections, morbidity and mortality. However, the article 
shows that it is not possible to detect such an effect among HIV positive people who use drugs in 
Vancouver. As Milloy et al. state, this is reassuring, given the imminent legalization of cannabis in 
Canada. 
Many of the remaining articles in the issue focus on drawing policy lessons from the experiences and  
hurdles encountered by the first movers in this space.    For example, Carnevale and colleagues (this 
issue) use the Colorado and Washington experience to offer recommendations for jurisdictions 
considering adopting a commercial, for-profit system with respect to (1) cultivation, production and 
processing; (2) sale, consumption and possession; (3) taxes and finance, (4) public health and safety; 
and (5) governance.  In both states regulations that were initially adopted related to these issues 
continued to evolve as the policy got implemented.  They recommend that states and other 
jurisdictions begin by adopting relatively restrictive regulatory approaches that can be subsequently 
loosened should they prove unnecessary or overly restrictive. History has demonstrated that it is 
much easier to loosen a tight market than to tighten a loose one.   
In another article, Subritzky, Pettigrew and Lenton (this issue)  get  into the weeds by discussing a 
specific area of growing public safety concern in Colorado; the application of pesticides and plant 
growth regulators used in the cultivation of legal cannabis.  They review the literature examining the 
chemical residue found on plant material typically smoked, and raise awareness of a study showing 
that the pesticide levels in concentrated cannabis products (waxes and edibles) are actually ten 
times higher than those found on the flower heads of the cannabis plants themselves.  Apparently, 
the cannabinoid extracting process that creates high THC products actually intensifies the levels of 
pesticides in the processed products, and these concentrated products are not currently being 
tested for pesticides by regulators.    They note that standardization of cannabis testing protocols in 
the United States has been a major challenge, given the variation between state and federal laws, 
issues of intellectual property in methods used to test products, and the complex naturally occurring 
chemical constituents of the various strains of the plant.  This article in particular provides highly 
valuable information for other jurisdictions interested in carefully thinking through all the details 
involved in developing product safety regulation and the technological needs and guidelines 
necessary to guarantee product safety.    
In  “From Toques to Tokes: Two Challenges Facing Nationwide Legalization of Cannabis in Canada” , 
Dr. Daniel Bear (this issue) discusses two major hurdles that current Canadian Task force will have to 
grapple with in its efforts to design a legal cannabis system within Canada.  The first is an issue that 
applies to all countries considering cannabis legalization, and that is the restrictions imposed by UN 
drug control treaties related to cannabis legalization.  The second hurdle is specific to the Canadian 
situation, and relates to the complexities of the interprovincial trade policies that have already 
impeded the selling of beer and wine between provinces in Canada.    This article is a valuable 
reminder that cannabis is not considered by government bureaucracies as “just another good”, even 
if that is how the populist sees it. 
Dr. Julia Dickey argues that we must pay attention to local implementation of these policies in 
evaluating them.   In most of the U.S. states that have passed legal cannabis, local jurisdictions are 
given the authority to decide if they would like to allow cannabis sales within their communities and 
under what conditions.    Therefore, even if a state passes a law, it does not imply uniform access to 
cannabis across the state.  Dr. Dilley and her colleagues demonstrate that as of June 2016 (four years 
after legalization in Washington and two years after stores opened in some areas), 30% of 
Washington state’s population lived in places that had temporarily or permanently banned retail 
sales.   Moreover, she notes how these laws continue to change over time, suggesting that 
evaluations looking at state aggregated data may not necessarily reflect the variability in local 
experiences caused by differences in whether and how these policies get implemented.   
Despite such difficulties, the articles collected in this issue demonstrate that it possible to apply 
rigorous analytical and empirical methods to develop knowledge on the effect of cannabis policy. 
The article by Grbic et al. (this issue) reminds us that evidence is not sufficient on its own to produce 
policy. A wide range of different types of knowledge and motivation also play a role. As Dr. Keith 
Humphreys noted at the ISSDP’s annual conference in 2009, values have a legitimate role in drug 
policy decisions (Humphreys, 2009; Humphreys & Piot, 2012). The lesson we take from Grbic et al’s 
article, and from our work and discussions with colleagues in the field, is that the production and 
dissemination of sound evidence is a vital part of the democratic process of policy construction. 
Researchers have a duty to produce evidence that is methodologically sound and to make it 
available to the public for use in public deliberation. 
The uses that will be made of evidence on cannabis policy in the Americas has been called into 
question by the result of the US presidential election in November 2016. At the April meeting, 
Caulkins suggested that the spread of cannabis legalization across the USA was ‘inevitable’. A state 
with a neighbour that legalizes cannabis will experience much the same harms (e.g. from residents 
using cannabis purchased in the neighbouring states), but little of the benefit (e.g. from tax 
revenue). So, in Schelling-esque style (Schelling, 1978), the often-displayed map of US states is 
bound to show the spread of legalization from state to state, even if no central power has directed 
this to happen. In his discussant’s response, Dr. Robert MacCoun argued that the spread of 
legalization is indeed ‘evitable’. The previous spread of decriminalization in the 1970s was halted by 
political developments that few would have predicted at the time. The election of President Trump 
represents another largely unpredicted event.   The Trump administration has provided no indication 
of its enthusiasm for or tolerance of the current state experimentation with legal cannabis, and the 
appointment of Sen Jeff Sessions as Attorney General provides no additional insight.   So it is remains 
unclear as to whether the United States will continue down its current path, or experience some 
intense internal conflict.  Only time will tell.   
We would like to close this editorial by thanking all the participants in the 2016 meeting, and 
especially Mark Kleiman and the team at BOTEC who put so much work into the event. Kleiman 
opened the event by declaring the Marron Institute’s agnosticism on the issue of cannabis 
legalisation, which is shared by the ISSDP. In the closing session, Peter Reuter (founding President of 
ISSDP) reminded us that it will take many years until we have a convincing picture of the effects of 
recent policy changes. We invite our readers – and future contributors to this journal and to events 
of the ISSDP – to continue the efforts to expand the scope of our knowledge on these topics, even if 
we cannot expect this knowledge to have a direct and decisive impact on policy in the short run. 
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